CSIMarket
 
Kalvista Pharmaceuticals Inc   (KALV)
Other Ticker:  
 
 
Price: $11.9300 $-0.50 -4.023%
Day's High: $12.56 Week Perf: -8.93 %
Day's Low: $ 11.87 30 Day Perf: -17.15 %
Volume (M): 792 52 Wk High: $ 16.88
Volume (M$): $ 9,453 52 Wk Avg: $10.26
Open: $12.42 52 Wk Low: $6.26



 Market Capitalization (Millions $) 412
 Shares Outstanding (Millions) 35
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -101
 Cash Flow (TTM) (Millions $) 19
 Capital Exp. (TTM) (Millions $) 0

Kalvista Pharmaceuticals Inc
Kalvista Pharmaceuticals Inc is a biopharmaceutical company that specializes in the development and commercialization of small molecule protease inhibitors for the treatment of serious orphan and rare diseases. The company's primary focus is on creating innovative therapies for diseases affecting the eyes, such as hereditary angioedema and diabetic macular edema.

Kalvista's drug candidates are designed to target proteases, which are enzymes that play a role in various diseases by causing excessive vascular permeability and inflammation. By inhibiting these proteases, Kalvista aims to reduce the symptoms and progression of these diseases.

The company utilizes its proprietary drug discovery platform to identify and develop new drug candidates. This platform combines structural biology, medicinal chemistry, and drug development expertise to rapidly advance molecules from discovery through preclinical and clinical development.

Kalvista Pharmaceuticals Inc is based in the United States and collaborates with academic institutions, healthcare organizations, and other pharmaceutical companies to accelerate the advancement of its therapies. The company is committed to improving the lives of patients suffering from rare and orphan diseases through innovative treatments.


   Company Address: 55 Cambridge Parkway Cambridge 2142 MA
   Company Phone Number: 999-0075   Stock Exchange / Ticker: NASDAQ KALV
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

KalVista Pharmaceuticals Evolving HAE Treatment with Real-World Data and Innovations

Published Mon, Mar 18 2024 10:30 AM UTC

In recent updates, KalVista Pharmaceuticals, a clinical stage pharmaceutical company, has presented new findings and data at various conferences, emphasizing the impact of treatment delays on the clinical outcomes of individuals living with hereditary angioedema (HAE). Moreover, the company has showcased additional data from its phase 3 KONFIDENT trial, shedding light on the...

Product Service News

KalVista Pharmaceuticals Receives UK Designations and Presents Promising Data for Sebetralstat at AAAAI Annual Meeting

Published Tue, Mar 12 2024 10:30 AM UTC

KalVista Pharmaceuticals, a renowned clinical stage pharmaceutical company specializing in the development and commercialization of oral, small molecule protease inhibitors, proudly announces multiple achievements in the field of hereditary angioedema (HAE) treatment. The UK Medicines and Healthcare products Regulatory Agency (MHRA) has awarded the company the prestigious Pr...

Business Update

KalVista Pharmaceuticals Sets Promising New Paradigm in Hereditary Angioedema Treatment, Progressing with Clinical Trials and Achieving Financial Milestones

Published Mon, Mar 11 2024 10:30 AM UTC

KalVista Pharmaceuticals Advances in Clinical Trials and Financial Performance, Pursuing Promising Therapies for Hereditary AngioedemaCAMBRIDGE, Mass. & SALISBURY, England- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a renowned clinical-stage pharmaceutical company specializing in the discovery, development, and commercialization of oral, small molecule protease inhibitor...

Product Service News

KalVista Pharmaceuticals Set to Present Promising HAE Attack Journey Data at 2024 HAEi Regional Conference Americas

Published Fri, Mar 8 2024 11:30 AM UTC

aims to provide an and comprehensive analysis of recent developments in the pharmaceutical industry. In this article, we will outline the key facts from the articles KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas and Relationship Between Tim concerning the upcoming presentation by KalVista Pharmaceuticals at the 2024 H...

Management Changes

KalVista Pharmaceuticals Appoints Benjamin L. Palleiko as CEO to Drive Growth and Overcome Challenges

Published Thu, Mar 7 2024 11:30 AM UTC



KalVista Pharmaceuticals, a clinical stage pharmaceutical company specializing in oral, small molecule protease inhibitors, has recently announced the appointment of Benjamin L. Palleiko as its new Chief Executive Officer (CEO). This crucial leadership change comes at a challenging time for KalVista, as the company experienced a significant decline in its share val...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com